| Presentation preference | Oral presentation |
| Title | Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Survey Among Early-Adopting Physicians |
| Purpose | Triamcinolone acetonide injectable suspension (SCS-TA; Xipere®) for suprachoroidal use was recently approved in the US for the treatment of uveitic macular edema (UME). Here, experience with the injection procedure among early adopters of SCS-TA along with patient outcomes were evaluated |
| Methods | Twelve retina/uveitis specialists were surveyed with a series of pre-defined questions probing their experience with SCS-TA |
| Results | Across respondents, at least 291 SCS-TA injections were administered to 243 patients with various uveitis etiologies, chronicity, and anatomical subtypes. Reasons for SCS-TA adoption included the potential lower risk for intraocular pressure elevations (n=12;100%) and longer duration of action (n=11;92%) versus intravitreal steroids/implants. Nearly all specialists (n=11;92%) found the injection somewhat/very easy post-training, with most (n=9;75%) procedurally comfortable after 2-5 injections. Patients typically gained 2-3 lines of vision by first follow-up visit, ~4-6 weeks post-injection, and most specialists (n=11;92%) reported 100 to ≥150 μm reductions in central subfield thickness. There were no unexpected/new safety findings. Most (n=11;92%) respondents were satisfied with SCS-TA treatment. |
| Conclusion | Perceptions and experiences of early adopters with treatments involving new delivery techniques can reveal educational gaps and provide real world evidence. Physicians found SCS-TA injection easy to learn with patient improvements in vision and in macular edema aligned with clinical trial data. |
| Conflict of interest | Yes |
| Details of conflicting interests | Consultant for Bausch and Lomb |
Authors 1
| Last name | EMAMI |
| Initials of first name(s) | P |
| Department | Ophthalmology |
| City | Sacramento, CA |
| Country | United States |
Authors 2
| Last name | Xipere Early adopters Survey Participants |
| Initials of first name(s) | - |
| Department | Ophthalmology |
| City | - |
| Country | United States |
